Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dlx4os siRNA
- Development stage
- Preclinical
- Lead developer
- Federal University of São Paulo
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intratumoral
01
Overview
dlx4os siRNA is a small interfering RNA (siRNA) designed to silence the expression of the long non-coding RNA (lncRNA) *Dlx4os*. *Dlx4os* has been identified as a transcript associated with malignant melanocyte transformation and epithelial-to-mesenchymal transition (EMT) in melanoma. In preclinical models, the downregulation of *Dlx4os* using this siRNA has been shown to alter the expression of EMT-related genes such as Snail1, Sox10, and Mitf, leading to the inhibition of cell migration in vitro and the suppression of tumorigenesis in vivo. This research was primarily conducted by investigators at the Federal University of São Paulo and the Harvard Medical School Initiative for RNA Medicine.
- Other names
- Dlx4os siRNADlx-4os siRNADlx 4os siRNA
02
Targets
Dlx4os (Dlx4 opposite strand long non-coding RNA)
Beyond the preview
Go deeper on dlx4os siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dlx4os siRNA.